Loading posts...
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
View

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

“This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center o...